Literature DB >> 2434802

Perindopril, converting enzyme blockade, and peripheral arterial hemodynamics in the healthy volunteer.

C Richer, C Thuillez, J F Giudicelli.   

Abstract

The effects of three doses (4, 8, and 16 mg) of perindopril, a new angiotensin I converting enzyme inhibitor, on systemic blood pressure, heart rate, brachial and carotid artery flow and diameter (assessed by the pulsed Doppler technique), forearm vascular resistance, plasma converting enzyme and renin activities, and plasma aldosterone were investigated in the normal volunteer and compared with those of a placebo over a 24-h period following oral drug intake in a double-blind, crossover trial. Perindopril dose-dependently decreased plasma converting enzyme activity, an effect that peaked at 3-4 h and persisted up to at least 48 h. Plasma renin activity increased for 12 h and plasma aldosterone was slightly decreased. Systemic blood pressure and heart rate were not drug-affected but perindopril dose-dependently augmented brachial and carotid artery flow, indicating an increase in peripheral arterial compliance. These vasodilating effects, which lasted up to 10 h after drug intake, affected both large arteries and arterioles, the latter being more sensitive, however, and were more marked in the muscular resistance vessels.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2434802

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  14 in total

1.  Non invasive study of systemic and regional haemodynamic and cardiac effects of a new calcium antagonist, SR 33557, in healthy volunteers.

Authors:  E Bellissant; C Thuillez; R Kechrid; P Duhaze; J F Giudicelli
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  The pharmacokinetics of perindopril in patients with liver cirrhosis.

Authors:  M Thiollet; C Funck-Brentano; J D Grangé; M Midavaine; G Resplandy; P Jaillon
Journal:  Br J Clin Pharmacol       Date:  1992-03       Impact factor: 4.335

Review 3.  Perindopril. A review of its pharmacokinetics and clinical pharmacology.

Authors:  R J Macfadyen; K R Lees; J L Reid
Journal:  Drugs       Date:  1990       Impact factor: 9.546

Review 4.  First-line treatment in hypertension. Role of perindopril.

Authors:  A Zanchetti
Journal:  Drugs       Date:  1990       Impact factor: 9.546

Review 5.  Perindopril: an updated review of its use in hypertension.

Authors:  M Hurst; B Jarvis
Journal:  Drugs       Date:  2001       Impact factor: 9.546

6.  Arterial vasodilating profile and biological effects of pinacidil in healthy volunteers.

Authors:  C Thuillez; E Pussard; E Bellissant; C Richer; R Kechrid; J F Giudicelli
Journal:  Br J Clin Pharmacol       Date:  1991-01       Impact factor: 4.335

7.  Changes in indocyanine green kinetics after the administration of enalapril to healthy subjects.

Authors:  J Geneve; T Le Dinh; A Brouard; M Bails; J M Segrestaa; C Caulin
Journal:  Br J Clin Pharmacol       Date:  1990-08       Impact factor: 4.335

8.  Comparison of the pharmacokinetics and pharmacodynamics of oral doses of perindopril in normotensive Chinese and Caucasian volunteers.

Authors:  P J Anderson; J A Critchley; B Tomlinson; G Resplandy
Journal:  Br J Clin Pharmacol       Date:  1995-04       Impact factor: 4.335

9.  Systemic and renal haemodynamic effects of angiotensin converting enzyme inhibition by zabicipril in young and in old normal men.

Authors:  R Naeije; A Fiasse; E Carlier; M Opsomer; M Leeman
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

10.  Effects of an angiotensin converting enzyme inhibitor, ramipril, on intracranial circulation in healthy volunteers. off.

Authors:  P Demolis; S Chalon; D Annane; P Duhaze; J F Giudicelli
Journal:  Br J Clin Pharmacol       Date:  1992-09       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.